A Study Comparing Ponatinib and Nilotinib in Patients With Chronic Myeloid Leukemia
Status:
Completed
Trial end date:
2021-01-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy and safety of 2 starting doses of
ponatinib compared to nilotinib in patients with imatinib-resistant chronic myeloid leukemia
(CML) in chronic phase (CP).